1. Home
  2. ACAD vs JOE Comparison

ACAD vs JOE Comparison

Compare ACAD & JOE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACAD
  • JOE
  • Stock Information
  • Founded
  • ACAD 1993
  • JOE 1936
  • Country
  • ACAD United States
  • JOE United States
  • Employees
  • ACAD N/A
  • JOE N/A
  • Industry
  • ACAD Biotechnology: Pharmaceutical Preparations
  • JOE Homebuilding
  • Sector
  • ACAD Health Care
  • JOE Real Estate
  • Exchange
  • ACAD Nasdaq
  • JOE Nasdaq
  • Market Cap
  • ACAD 2.8B
  • JOE 2.7B
  • IPO Year
  • ACAD 2004
  • JOE N/A
  • Fundamental
  • Price
  • ACAD $14.73
  • JOE $42.66
  • Analyst Decision
  • ACAD Buy
  • JOE
  • Analyst Count
  • ACAD 16
  • JOE 0
  • Target Price
  • ACAD $23.93
  • JOE N/A
  • AVG Volume (30 Days)
  • ACAD 1.8M
  • JOE 298.2K
  • Earning Date
  • ACAD 05-07-2025
  • JOE 04-23-2025
  • Dividend Yield
  • ACAD N/A
  • JOE 1.31%
  • EPS Growth
  • ACAD N/A
  • JOE N/A
  • EPS
  • ACAD 1.36
  • JOE 1.27
  • Revenue
  • ACAD $957,797,000.00
  • JOE $402,737,000.00
  • Revenue This Year
  • ACAD $13.07
  • JOE N/A
  • Revenue Next Year
  • ACAD $9.88
  • JOE N/A
  • P/E Ratio
  • ACAD $10.83
  • JOE $33.59
  • Revenue Growth
  • ACAD 31.85
  • JOE 3.46
  • 52 Week Low
  • ACAD $13.40
  • JOE $40.19
  • 52 Week High
  • ACAD $20.68
  • JOE $64.69
  • Technical
  • Relative Strength Index (RSI)
  • ACAD 38.07
  • JOE 41.25
  • Support Level
  • ACAD $14.34
  • JOE $42.01
  • Resistance Level
  • ACAD $15.18
  • JOE $43.13
  • Average True Range (ATR)
  • ACAD 0.80
  • JOE 1.78
  • MACD
  • ACAD -0.02
  • JOE -0.20
  • Stochastic Oscillator
  • ACAD 38.22
  • JOE 34.84

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

About JOE St. Joe Company (The)

The St. Joe Co is a real estate development, asset management, and operating company and it has three operating segments; the Residential segment plans and develops residential communities and sells homesites to homebuilders or retail consumers, the Hospitality segment that derives maximum revenue, features a private membership club, hotel operations, food and beverage operations, golf courses, beach clubs, retail outlets, gulf-front vacation rentals, management services, marinas, and other entertainment assets, and Commercial segment include leasing of commercial property, multi-family, senior living, self-storage, and other assets and it also oversees the planning, development, entitlement, management, and sale of commercial and rural land holdings.

Share on Social Networks: